Skip to main content
    M

    Myriad Genetics Inc (MYGN)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $5.57
    -0.09 (-1.59%)

    Market Cap: $542.92M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Myriad Genetics Inc (MYGN) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Myriad Genetics are Fulgent Genetics (FLGT), Castle Biosciences (CSTL) and NeoGenomics (NEO). By market cap, Myriad Genetics ranks 10th of the 13 companies on this page; Natera (NTRA) is the largest at $46.27B. The median P/E of the 3 companies with a P/E is 48.2x.

    Peer Comparison

    MYGN's ROIC of -29.5% is below the peer median of -5.7%, and its revenue growth of -1.5% is below the median of 13.3%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Myriad Genetics (MYGN)$542.92MN/A0.7x-16.1%-29.5%-1.5%0.00%
    Fulgent Genetics Inc (FLGT)$688.98MN/A2.0x-27.5%-12.1%7.5%0.00%
    Castle Biosciences Inc (CSTL)$1.04BN/A2.7x-6.1%-5.4%23.9%0.00%
    NeoGenomics Inc (NEO)$2.07B228.9x2.6x-4.1%-2.5%11.4%0.00%
    Personalis Inc (PSNL)$1.70BN/A20.9x-147.7%N/A76.6%0.00%
    Veracyte Inc (VCYT)$1.96B13.3x3.3x21.8%8.2%15.1%0.00%
    Opko Health Inc (OPK)$1.25BN/A2.4x-22.6%-6.2%15.9%0.00%
    GRAIL, LLC (GRAL)$5.21BN/A29.6x-243.8%N/A3.7%0.00%
    MDxHealth SA (MDXH)$13.75MN/AN/A-38.3%-40.5%-17.2%0.00%
    Natera Inc (NTRA)$46.27BN/A14.3x-5.7%-8.5%34.1%0.00%
    Insight Molecular Diagnostics Inc. (IMDX)$70.03MN/A40.9x0.0%197.8%-53.9%0.00%
    CareDx Inc (CDNA)$4.09B48.2x6.4x25.9%N/A39.3%0.00%
    Precipio Inc (PRPO)$39.68MN/A1.3x-4.1%-5.7%8.3%0.00%
    Peer median$1.48B48.2x3.3x-5.9%-5.7%13.3%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Myriad Genetics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Diagnostics & Research.

    CompanyAboutPeers
    Fulgent Genetics Inc (FLGT)
    Fulgent Genetics, Inc., provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information.
    FLGT competitors
    Castle Biosciences Inc (CSTL)
    Castle Biosciences Inc. is a pioneering diagnostics firm that enhances patient care through advanced gene-expression profiling tests...
    CSTL competitors
    NeoGenomics Inc (NEO)
    NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia.
    NEO competitors
    Personalis Inc (PSNL)
    Personalis, Inc. is a global cancer genomics company. The company is headquartered in Menlo Park, California.
    PSNL competitors
    Veracyte Inc (VCYT)
    Veracyte, Inc. is a genomic diagnostics company in the United States and internationally. The company is headquartered in South San Francisco, California.
    VCYT competitors
    Opko Health Inc (OPK)
    OPKO Health, Inc., a healthcare company, is engaged in the pharmaceutical and diagnostic businesses in the United States, Ireland, Chile, Spain, Israel, Mexico...
    OPK competitors
    GRAIL, LLC (GRAL)
    GRAIL, LLC is a leading biotechnology firm specializing in advanced cancer diagnostics...
    GRAL competitors
    MDxHealth SA (MDXH)
    MDxHealth SA is a prominent biotechnology company focused on precision diagnostics that enhance cancer management, particularly in prostate and bladder cancers.
    MDXH competitors
    Natera Inc (NTRA)
    Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.
    NTRA competitors
    Insight Molecular Diagnostics Inc. (IMDX)
    OncoCyte Corporation is a precision diagnostics company in the United States and internationally. The company is headquartered in Irvine, California.
    IMDX competitors
    CareDx Inc (CDNA)
    CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally.
    CDNA competitors
    Precipio Inc (PRPO)
    Precipio, Inc., a cancer diagnostic and reagent technology company, provides diagnostic products and services in the United States oncology market.
    PRPO competitors

    Frequently Asked Questions About MYGN

    Who are Myriad Genetics' main competitors?

    The companies most similar to Myriad Genetics include Fulgent Genetics (FLGT), Castle Biosciences (CSTL), NeoGenomics (NEO), Personalis (PSNL) and Veracyte (VCYT), listed from the closest match.

    Who is Myriad Genetics' biggest competitor?

    Natera (NTRA) is the largest of the similar companies at $46.27B; Fulgent Genetics (FLGT) is the closest match by business profile, size, sector and industry.

    How does MYGN stock compare with its competitors?

    MYGN's P/S is 0.7x against a peer median of 3.3x; its net margin is -16.1% against a peer median of -5.9%.

    Which of Myriad Genetics' competitors pays a higher dividend?

    Myriad Genetics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Myriad Genetics bigger than its competitors?

    No. Myriad Genetics is 10th by market cap among the 13 companies on this page; the largest is Natera (NTRA) at $46.27B.